Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Approvals Analysis: FDA Makes Efficiency Mark For PMAs

Executive Summary

The US agency achieved its most efficient performance in the past 15 years for original PMA submission reviews in the most recently completed application cohort. PMA approval volumes also remain healthy. Meanwhile, 510(k) review times have leveled off and clearance volumes have dropped slightly.

You may also be interested in...



MDUFA IV Takes Shape: A Catalogue Of Draft Commitments

More specific details have emerged about the agreement "in principle" announced last week by FDA and industry negotiators on the next round of the medical device user-fee program, which will extend from fiscal years 2018 through 2022.

FDA Approves Edwards' Rapid-Deployment Minimally Invasive Surgical Valve

The system combines the company's proven tissue surgical valve platform with technology developed for transcatheter valves.

US Approvals Analysis: July A Good Month For PMAs; 510(k)s Down In 2016

A look at Medtech Insight's Approval Tracker data shows that last month was a relatively active one for US FDA approvals of novel devices via the PMA, panel-track supplement and de novo routes. But 510(k) clearance totals are down so far in 2016 compared to recent years.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel